We further focused on patients with lung cancer who were initially diagnosed with stage IV ADC, which included 36 patients harboring the METex14 mutation and 524 patients without major driver mutations (i.e., the non-METex14 group consisting of patients without detected METex14, EGFR, ALK, KRAS, HER2, BRAF V600E, ROS-1, and RET mutations) (Figure 1). This evidence concerns the gene KRAS and lung cancer.